T. Rowe Price Associates, Inc. 13D and 13G filings for Avidity Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-11-14 1:22 pm Purchase |
2024-09-30 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 10,633,962 9.000% |
977,110![]() (+10.12%) |
Filing |
2024-03-11 1:12 pm Purchase |
2024-02-29 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 9,656,852 12.100% |
2,738,942![]() (+39.59%) |
Filing |
2024-02-14 10:03 am Purchase |
2023-12-31 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 6,917,910 9.300% |
210,623![]() (+3.14%) |
Filing |
2023-02-14 12:38 pm Purchase |
2022-12-31 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 6,707,287 10.100% |
1,627,761![]() (+32.05%) |
Filing |
2022-08-10 2:56 pm Sale |
2022-07-31 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 5,079,526 10.200% |
-2,652,320![]() (-34.30%) |
Filing |
2022-02-14 2:35 pm Purchase |
2021-12-31 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 7,731,846 16.400% |
1,916,636![]() (+32.96%) |
Filing |
2021-09-10 1:36 pm Purchase |
2021-08-31 | 13G | Avidity Biosciences, Inc. RNA |
T. Rowe Price Associates, Inc. | 5,815,210 12.700% |
5,815,210![]() (New Position) |
Filing |